Q-omics provides the consensus-scored OGT profile across patient tissues and cancer cell-line models. OGT expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, OGT is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, OGT protein abundance shows 27,137 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, COAD, and GBM as cancer lineages where OGT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OGT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OGT survival associations across molecular data types. OGT RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OGT RNA expression–survival associations across cancer types. High OGT expression shows unfavorable associations in UCEC, UVM, KIRC and KICH, but favorable associations in BLCA and SKCM. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for OGT RNA expression.
This table summarizes OGT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for OGT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OGT shows lower tumor expression in BRCA and higher tumor expression in COAD, LIHC, HNSC, STAD and CHOL. The COAD box plot shows higher OGT RNA expression in tumor versus normal tissue (log2 FC = +1.418, t-test p < 0.001).
This table shows molecular features associated with OGT in patient tissues and cancer cell lines. In patient samples, OGT shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, OGT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
